Medesthetics

MAR 2014

MedEsthetics—business education for medical practitioners—provides the latest noninvasive cosmetic procedures, treatment trends, product and equipment reviews, legal issues and medical aesthetics industry news.

Issue link: https://medesthetics.epubxp.com/i/263224

Contents of this Issue

Navigation

Page 66 of 74

NEWS & EVENTS VALEANT ACQUIRES SOLTA MEDICAL Valeant Pharmaceuticals (valeant.com) has acquired Solta Medi- cal, a developer and marketer of aesthetic technologies—in- cluding Fraxel, Thermage, Liposonix and Vaser—for $2.92 per share in cash. "The acquisition of Solta will bring tremendous value to Valeant's current aesthetic portfolio and together with our pre- vious acquisitions, will create the broadest aesthetic portfolio in the industry," said J. Michael Pearson, chairman and CEO of Valeant. "Solta's leading aesthetic devices are a natural fi t with Valeant's facial injectables, professional skincare products and physician-dispensed products, and will establish Valeant in a strong leadership position as we continue to build our pres- ence in the aesthetic market." ALLERGAN AND MEDYTOX COMPLETE LICENSING AGREEMENT Allergan (allergan.com) and Korean-based Medytox have closed their license agreement, which was previously an- nounced in September 2013. Under the terms of the agree- ment, Allergan will pay Medytox $65 million U.S. upfront cash within seven business days of closing, and Medytox has granted Allergan exclusive rights, worldwide outside of Korea, to devel- op and, if approved, commercialize certain neurotoxin product candidates currently in development, including a potential liquid-injectable product. Pursuant to the agreement, Allergan will also make additional contingent payments, including up to an aggregate of $116.5 million U.S. upon achieving certain development milestones, up to an aggregate of $180.5 million U.S. upon achieving certain commercialization milestones, and royalties on product sales. MERZ ACQUIRES ANTEIS Merz Pharma Group announced that it has entered into a defi nitive agreement to acquire Anteis, a Swiss company that specializes in the development, manufacture and commercial- ization of aesthetic medical devices. Anteis is the developer and manufacturer of the Belotero family of dermal fi llers, including Belotero Balance, which is distributed exclusively by Merz. "The acquisition of Anteis by Merz is a unique opportunity to strengthen our presence in aesthetic medicine by bringing innovative solutions to doctors and patients," said Philip Bur- chard, CEO of Merz Pharma Group. "Anteis brings substantial additions to Merz in terms of products, talent, geographical presence and manufacturing capabilities. Our two portfolios complement each other perfectly." SUNEVA MEDICAL EXPANDS LICENSING AGREEMENT WITH HISTOGEN Suneva Medical, maker of Artefi ll long-term dermal fi ller and United States distributor of the Regenica skincare line, has amended its existing licensing agree- ment with Histogen to include distri- bution of the Regenica line through the physician-dispensed channel in Europe, most of Asia, South America, Canada, Australia, and the Middle East. "Regenica's growing customer base is a testament to the product's ability to rejuvenate the skin, acceler- ating the body's own cells' ability to repair and renew," stated Nicholas L. Teti Jr., chairman and CEO of Suneva Medical. "With this amended licensing agreement in place, international consumers will now have access to the latest U.S. growth factor technology." DERMATUDE WELCOMES MCELROY Crystal McElroy has joined Der- matude, makers of META Therapy microneedling equipment and topical skincare products, as national educator, and sales and account executive for Dermatude North America. She will oversee sales, ac- count management, marketing and education for the North American region. McElroy is a licensed clinical and medical esthetician with a diverse business background in the esthetics and beauty industry including sales, education, brand management, business development, event logistics and event management. META Therapy, which stands for Medical Esthetical Tissue Activation, makes thousands of micro-perforations in the skin delivering active ingredients, without downtime or the need for anesthetic. McElroy will be training practitioners in the U.S. through a one-day course that covers the benefi ts of META Therapy as well as information on how to market and pro- mote the treatment in spas and medspas. For more informa- tion, contact 855.309.0313, c.mcelroy@dermatude.com. RAETZMAN NAMED CEO OF GALDERMA Galderma S.A. has appointed industry veteran Stuart Raetzman to CEO of Galderma Laboratories, L.P. and vice president, North America. The position became effective March 1, 2014. Raetzman was also elected to the company's Global Executive Committee and will report directly to Hum- berto C. Antunes, president and CEO of Galderma S.A. Raetzman previously worked with Alcon, a division of Novartis, for 20 years, holding senior leadership roles in the U.S. and Europe. "This leadership appointment comes at a moment of great change in the dermatology industry and for those who provide services to patients," said Antunes. "Galderma is committed to providing innovative medical 62 MARCH 2014 | Med Esthetics CRYSTAL MCELROY N e w s E v e n t s M E D 3 1 4 . i n d d 6 2 News Events MED314.indd 62 2 / 1 1 / 1 4 4 : 0 0 P M 2/11/14 4:00 PM

Articles in this issue

Links on this page

Archives of this issue

view archives of Medesthetics - MAR 2014